Loading news...
OrbiMed Advisors increased its position in RAPT Therapeutics by 556,273 shares during the fourth quarter; the estimated trade size was $17.28 million based on quarterly average pricing. The quarter-end value of the RAPT stake rose by $27.62 million, reflecting both additional shares and stock price appreciation.
Great Point Partners acquired 581,187 shares of RAPT Therapeutics in the fourth quarter. The quarter-end position value increased by $19.68 million due to the new position in RAPT Therapeutics.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation.
Rapt Therapeutics (NASDAQ: RAPT - Get Free Report) and Solid Biosciences (NASDAQ: SLDB - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability. Profitability This table compares Rapt Therapeutics and
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics, Inc. (NasdaqGM: RAPT) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of RAPT will receive $58.00 in cash for each share of RAPT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: RAPT Therapeutics, Inc.
BALA CYNWYD, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Rapt Therapeutics (NASDAQ: RAPT - Get Free Report)'s share price reached a new 52-week high on Friday. The company traded as high as $57.74 and last traded at $57.74, with a volume of 1321908 shares trading hands. The stock had previously closed at $57.63. Wall Street Analysts Forecast Growth Several equities research analysts have recently
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics, Inc. (NasdaqGM: RAPT) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of RAPT will receive $58.00 in cash for each share of RAPT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.
GSK agrees to buy RAPT Therapeutics for $2.2B, adding ozureprubart to its pipeline and strengthening its respiratory and immunology portfolio.
Market sentiment declined as Trump's trade stance intensified fears. CNN Fear and Greed index moved to 'Neutral' zone.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
GSK offered to buy Rapt Therapeutics for a sizable premium to its recent market value. Rapt's experimental antibody therapy could help millions of people who suffer from severe food allergies.
BALA CYNWYD, Pa., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating RAPT Therapeutics, Inc. (NASDAQ: RAPT) related to its sale to GSK plc.